1. ESMO Open. 2019 Sep 8;4(5):e000548. doi: 10.1136/esmoopen-2019-000548. 
eCollection 2019.

From crizotinib to lorlatinib: continuous improvement in precision treatment of 
ALK-positive non-small cell lung cancer.

Pirker R(1), Filipits M(1).

Author information:
(1)Internal Medicine I, Medical University of Vienna, Vienna, Austria.

DOI: 10.1136/esmoopen-2019-000548
PMCID: PMC6735665
PMID: 31555485

Conflict of interest statement: Competing interests: RP has received speaker's 
fees from AstraZeneca and Boehringer Ingelheim, honoraria for Advisory Boards 
from Boehringer Ingelheim, Jansen Oncology as well as Takeda, and honoraria for 
Data Monitoring Committee participation from Genmab, Gedeon Richter, Merck Sharp 
Dohme and Regeneron. MF has received speakerâ€™s fees and honoraria for Advisory 
Boards from AstraZeneca, Bayer, Biomedica, Boehringer Ingelheim, Eli Lilly, 
Merck, Myriad Genetics, Pfizer, and Roche.